Welcome to our dedicated page for VRAY news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on VRAY stock.
ViewRay, Inc. (Nasdaq: VRAY) pioneers MRI-guided adaptive radiotherapy through its MRIdian® system, which enhances cancer treatment precision with real-time imaging and adaptive dosing. This page aggregates official announcements, financial updates, and clinical milestones for investors and healthcare professionals tracking advancements in radiation therapy technology.
Key resources include: Press releases on MRIdian® installations like the VA Oklahoma City partnership, earnings reports, regulatory clearances, and research collaborations. Stay informed on ViewRay's role in expanding access to non-invasive therapies that prioritize patient safety and outcomes.
Bookmark this page for streamlined access to verified updates about VRAY's innovations in medical technology. Visit regularly to monitor developments in MRI-guided treatment adoption and ViewRay's global impact on oncology care.
NUBURU has appointed Brian Knaley as Chief Financial Officer, bringing over 25 years of experience, including roles at CEA Industries (Nasdaq: CEAD), ViewRay (Nasdaq: VRAY), and ARC Group Worldwide (Nasdaq: ARCW). His expertise will enhance NUBURU's financial processes and support its growth strategy in blue laser technology. Mr. Knaley previously raised $3 million in a PIPE financing for CEA Industries and has a proven track record of optimizing financial functions.
ViewRay, Inc. (NASDAQ: VRAY) announced that University Hospital Agostino Gemelli has treated over 1,000 patients with its MRIdian MRI-guided radiation therapy, marking a significant milestone in Southern Europe. Starting in February 2017, the center utilized MRIdian technology to enhance treatment precision for tumors. Notably, over 50% of procedures involve stereotactic body radiation therapy, especially for liver and pancreatic cancers. This system offers real-time imaging and tracking, reducing damage to healthy tissue. Currently, 50 MRIdian systems are operational globally, with nearly 18,000 patients treated.
ViewRay, Inc. (Nasdaq: VRAY) will host a Virtual Clinical Data Event on March 16, 2022, at 4:00 pm ET. The event will highlight clinical trials, specifically the MIRAGE and SCIMITAR studies in prostate cancer radiation therapy, featuring Dr. Amar Kishan from UCLA and Dr. Himanshu Nagar from Weill Cornell Medicine. Registration is available on their website, and a replay will be accessible post-event. ViewRay focuses on developing the MRIdian® MR-Guided Radiation Therapy System, designed to enhance radiation oncology.
ViewRay, Inc. (NASDAQ: VRAY) has announced promising results from the Phase II SCIMITAR trial, showing that MRI-guided radiation therapy significantly reduces acute gastrointestinal (GI) toxicity by 30.5% compared to CT-guided treatment. The trial evaluated 100 patients who underwent stereotactic body radiotherapy (SBRT) post-prostatectomy. Findings revealed no instances of grade 3 toxicity among patients treated with MRI guidance. These results were presented at the ACRO 2022 summit, indicating potential advancements in prostate cancer treatment.
ViewRay, Inc. (NASDAQ: VRAY) announced the appointment of Susan Schnabel to its Board of Directors as an independent director, effective March 8, 2022. Schnabel brings extensive financial and operational expertise. The company has also engaged Sai Nanduri from Hudson Executive Capital (HEC) as a consultant to improve shareholder returns, with HEC owning about 8.8% of the company’s common stock. In connection, ViewRay has entered a cooperation agreement with HEC. Kevin Xie resigned from the board on the same date, resulting in a board of nine members, eight of whom are independent.
ViewRay, Inc. (NASDAQ: VRAY) announced the sale of a second MRIdian MRI-guided radiation therapy system to Acibadem Group for installation at Acibadem Altunizade Hospital in Istanbul, Turkey. Acibadem has been utilizing an MRIdian since September 2018, aiding in treatments for various cancers. This new system aims to enhance capabilities in neuro-oncology and thoracic-oncology. The MRIdian system is designed for real-time tracking and adaptive therapy, treating nearly 18,000 patients worldwide and featuring 50 installations globally.
ViewRay, Inc. (Nasdaq: VRAY) reported its financial results for Q4 and full year 2021, showcasing a revenue increase to $70.1 million, up from $57.0 million in 2020. The company secured 28 orders worth $158.9 million, boosting its backlog to $313.4 million. For Q4 2021, revenue was approximately $20.4 million, with seven new system orders worth $40.7 million. Despite these gains, the company reported a net loss of $110 million for the year. Looking ahead, ViewRay forecasts 2022 revenue between $84 million and $104 million.
On February 15, 2022, ViewRay (NASDAQ: VRAY) announced interim data from the Phase III MIRAGE trial, led by UCLA, which highlights the superiority of MRIdian MRI-guided SBRT over CT-guided SBRT in treating localized prostate cancer. The interim analysis showed a significant reduction in acute grade ≥2 GU toxicity (22.4% vs. 47.1%) and gastrointestinal toxicity (0% vs. 13.7%) in patients receiving MRI-guided treatment. Due to compelling results, the trial's sample size was reduced from 300 to 154, maintaining 89% power for superiority. The final analysis is expected in early 2022.
ViewRay, Inc. (Nasdaq: VRAY) has announced a conference call scheduled for February 24, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results. Domestic callers can dial (844) 277-1426, while international callers should use (336) 525-7129. A live webcast will also be available on the company's investor relations page. ViewRay specializes in the MRIdian® MR-Guided Radiation Therapy System, designed for advanced radiation oncology applications, addressing challenges such as beam distortion and skin toxicity.
ViewRay, Inc. (NASDAQ: VRAY) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022. Chief Financial Officer Zach Stassen and VP of Clinical Affairs Paul Strong will host a virtual fireside chat at 3:00 p.m. Eastern Time. The conference is exclusive to BTIG clients, and interested parties should contact their BTIG representative to attend. ViewRay designs and markets the MRIdian MR-Guided Radiation Therapy System, addressing unique challenges in advanced radiation oncology.
